# Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

> **NCT00298363** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 112 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir disoproxil fumarate (tenofovir DF; TDF)
- **DRUG:** Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
- **DRUG:** Entecavir (ETV)
- **DRUG:** TDF placebo
- **DRUG:** FTC/TDF placebo
- **DRUG:** ETV placebo

## Key facts

- **NCT ID:** NCT00298363
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2013-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298363, "Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00298363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*